Interim Data from this Cutaneous T-Cell Lymphoma Trial is Looking Promising
source: pixabay.com

Interim Data from this Cutaneous T-Cell Lymphoma Trial is Looking Promising

According to a story from BioSpace, the biopharmaceutical company Bioniz Therapeutics, Inc., has recently announced the release of interim results from its phase 1/2 clinical trial. This trial is investigating…

Continue Reading Interim Data from this Cutaneous T-Cell Lymphoma Trial is Looking Promising
Company Releases Early Clinical Data For Experimental Blood Cancer Drug
SarahMarciano / Pixabay

Company Releases Early Clinical Data For Experimental Blood Cancer Drug

According to a story from pm360online.com, the biopharmaceutical company miRagen Therapeutics, Inc., recently presented Phase I clinical trial data regarding the company's experimental drug cobomarsen. This data was presented at…

Continue Reading Company Releases Early Clinical Data For Experimental Blood Cancer Drug

The Cutaneous Lymphoma Foundation’s Patient Conference

  • Post author:
  • Post category:

The 2019 2-Day Patient Conference Manhattan Beach, California Are you a cutaneous T-cell lymphoma patient? Well don’t miss this important patient event. At this conference, cutaneous T-cell lymphoma patients and…

Continue Reading The Cutaneous Lymphoma Foundation’s Patient Conference
A New Drug May Be Coming to the Market for Cutaneous T-cell Lymphoma
https://pixabay.com/en/youth-active-jump-happy-sunrise-570881/

A New Drug May Be Coming to the Market for Cutaneous T-cell Lymphoma

A phase 3 clinical trial has produced positive results for cutaneous T-cell lymphoma (CTCL) patients. The drug tested is called brentuximab vedotin (Adcetris). Specifically, the drug was created to treat…

Continue Reading A New Drug May Be Coming to the Market for Cutaneous T-cell Lymphoma